The results of the NIAGARA trial have considerably advanced treatment for patients with muscle-invasive bladder cancer, establishing a new therapeutic standard for cisplatin-eligible patients. Future trials will help to answer remaining questions about perioperative treatment optimization.
- Stephan Brönimann
- Shahrokh F. Shariat